Table 1.
Baseline patients' and tumor characteristics.
| Patient characteristics | All patients (n = 148) |
|---|---|
| Age at diagnosis, median [IQR] | 35.5 [31.5–38] |
| AMH, median [IQR] | 1.68 [1.00–3.30] |
| AMH, mean [SD] | 2.55 [2.81] |
| Body mass index (kg/m2), median [IQR] | 22.7 [21.0–26.2] |
| Smoker, n (%) | 52 (35%) |
| Genetic mutation, n (%) | 35 (24%) |
| BRCA1 | 22 (63%) |
| BRCA2 | 13 (37%) |
| Tumor characteristics, n (%) | |
| Histological grade | |
| Grade I | 6 (4%) |
| Grade II | 54 (36%) |
| Grade III | 87 (59%) |
| Not available | 1 (<1%) |
| Hormone receptor positivity | 92 (62%) |
| Oestrogen receptor | 90 (61%) |
| Progesteron receptor | 65 (44%) |
| HER2-positive | 27 (18%) |
| Triple-negative | 52 (35%) |
| Pathological nodal status positivity | 77 (52%) |
| Tumor size (T) | |
| T1 | 49 (33%) |
| T2 | 72 (49%) |
| T3 | 23 (15%) |
| T4 | 4 (3%) |
| Surgical treatment, n (%) | |
| Conservative | 82 (55%) |
| Mastectomy | 66 (45%) |
| Adjuvant treatment, n (%) | |
| Radiation therapy | 144 (97%) |
| Endocrine therapya | 90 (61%) |
| Chemotherapy | 148 (100%) |
| Chemotherapy regimen, n (%) | |
| 3 FEC−3 D | 127 (86%) |
| 6 FEC | 21 (14%) |
| Endocrine therapy, n (%) | |
| Tamoxifen | 82 (91%) |
| Tamoxifen + GnRH agonists | 8 (9%) |
| Fertility history, n (%) | |
| Pregnancy before treatment | 129 (84%) |
| Childbirth before treatment | 128 (84%) |
a
2 patients with hormone receptor-positive tumors refused endocrine therapy.
AMH, anti-mullerian hormone; IQR, interquartile range; SD, standard deviation; FEC, fluorouracil, epirubicin, cyclophosphamide; D, docetaxel; GnRH, gonadotropin-releasing hormone.